Melbourne Melanoma Project committed to improving the diagnosis and early detection of melanoma.

UV, Sex, and Age Contribute to Melanoma Tumor Evolution

Although ultraviolet (UV) radiation damage and clock-like mutations associated with cell division contribute to melanoma risk, sex, and age may represent the final mutational composition of skin cancer, according to study research published in the British Journal of Dermatology.

Melanoma Advances Improved OS in Patients With Brain Mets

Advances that emerged from 2007 – 2016 in the treatment of melanoma, including targeted agents, immunotherapy, and new radiotherapy techniques, led to significant improvement in overall survival for patients with melanoma and brain metastases, according to findings from a large population-based cohort study.

Dr. Chandra on the Incidence of Targetable Mutations in Melanoma

Sunandana Chandra, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the incidence of targetable mutations in melanoma.

Investigators Present Updated Results of the OpACIN Trial for Melanoma

Christian U. Blank, MD, PhD, medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, discusses the most recent data from the phase 1b OpACIN trial (NCT02437279) of ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with macroscopic stage III melanoma.